20735-74-4Relevant academic research and scientific papers
Conformational restraint is a critical determinant of unnatural nucleotide recognition by protein kinases
Ulrich, Scott M,Sallee, Nathan A,Shokat, Kevan M
, p. 3223 - 3227 (2002)
This report describes the synthesis of N4-(benzyl) AICAR triphosphate, a conformationally restrained analogue of N4-(benzyl) ribavirin triphosphate. Both of these nucleotides were evaluated as phosphodonors for wild-type p38 MAP kina
A Facile Synthesis of AICAR from Inosine
Kohyama, Naoki,Yamamoto, Yukio
, p. 2639 - 2642 (2003)
5-Amino-1-β-D-ribofuranosylimidazole-4-carboxamide (AICAR; 1) (Figure 1) was efficiently prepared from inosine through its 1-alkoxymethylderivatives. The stability of these derivatives enabled their purification by column chromatography (silica gel). The operation ensured the high quality of 1, which was obtained in good yield through alkaline hydrolysis of the derivatives.
Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support
Oliviero, Giorgia,Amato, Jussara,Borbone, Nicola,D'Errico, Stefano,Piccialli, Gennaro,Bucci, Enrico,Piccialli, Vincenzo,Mayol, Luciano
, p. 6475 - 6481 (2008/09/21)
Herein, we report the solid-phase synthesis of several 5-aminoimidazole-4-(N-alkyl)carboxamide-1-ribosides (4-N-alkyl AICARs) and the corresponding 2′,3′-secoriboside derivatives. The method uses the N-1-dinitrophenyl-inosine 5′-bonded to a solid support.
METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
-
Page/Page column 26, (2008/12/07)
The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit incl
METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
-
Page/Page column 79-80, (2010/11/24)
The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.
